Biodesix, Inc. · NASDAQ:BDSX

Biodesix — Investor Presentation (November 2026)

29 slides from Biodesix's investor presentation, November 2026

  1. Slide 1: Corporate Presentation

    Slide 1: Corporate Presentation

    Corporate Presentation Biodesix is a leading diagnostics company, driven to improve clinical care and outcomes for patients. November 2026

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral presentation have been prepared by Biodesix, Inc. ("Biodesix", “we” or the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise

  3. Slide 3: Biodesix is a leading diagnostics solutions company: mission and vision

    Slide 3: Biodesix is a leading diagnostics solutions company: mission and vision

    Biodesix is a leading diagnostics solutions company, driven to improve clinical care and outcomes for patients. MISSION VISION support clinical decisions to expedite personalized Our mission is to transform patient care We envision a world where patient diseases care and improve outcomes for patient

  4. Slide 4: 330+ team members driving two business lines

    Slide 4: 330+ team members driving two business lines

    330+ team members, across the USA, with deep science, technology, regulatory, and commercial expertise to drive our two business lines: Lung Diagnostic Tests Development Services Enabling the world’s leading Five on-market tests. Supporting clinical biopharmaceutical, life sciences, and decisions to

  5. Slide 5: Q3 2026 Financial Highlights

    Slide 5: Q3 2026 Financial Highlights

    Q3 2026 Financial Highlights Revised FY 2026 Revenue Guidance: $101 – 103M. Mid-point reflects 15% YoY growth. Total Lung Dx Devt Svcs Gross Net Revenues Revenues Revenues Margin Loss AEBITDA* Q3 2026 $24.0M $23.0M $1.0M 81% ($8.0M) ($3.9M) Year over +10% +16% (47%) maintained +8% +16% Year improvem

  6. Slide 6: Strategic Updates

    Slide 6: Strategic Updates

    Strategic Updates Digital Diagnostics • Expanding lung diagnostics to combine blood and imaging biomarkers with AI. • First product: a radiomics-based lung nodule risk test developed with Vanderbilt University and Vanderbilt Health to complement Nodify Lung® CHEST Updates: testing. • Lung Nodule Fra

  7. Slide 7: Two highly-certified, technologically-advanced laboratories

    Slide 7: Two highly-certified, technologically-advanced laboratories

    Two highly-certified, technologically-advanced laboratories LOUISVILLE, CO DE SOTO, KS CLIA certified CLIA certified CAP accredited CAP accredited NYS CLEP certified: Clinical Chemistry (limited to NYS CLEP certified: Clinical Chemistry (limited to soluble tumor markers), Oncology - Molecular & solu

  8. Slide 8: Lung Diagnostic Tests

    Slide 8: Lung Diagnostic Tests

    Lung Diagnostic Tests Our Core Commercial Clinical Offering

  9. Slide 9: What Drives Us: The Fight Against Lung Cancer

    Slide 9: What Drives Us: The Fight Against Lung Cancer

    What Drives Us: The Fight Against Lung Cancer 1 in 18 Lung cancer annual mortality vs other major People will be diagnosed with lung cancers cancer in their lifetime2 10% 120,000 PROSTATE 5-year survival for patients diagnosed with metastatic lung cancer3 90,000 BREAST 60,000 LUNG 1 in 5 Cancer deat

  10. Slide 10: Extensive Portfolio of Medicare-Covered Lung Diagnostic Tests

    Slide 10: Extensive Portfolio of Medicare-Covered Lung Diagnostic Tests

    Extensive Portfolio of Medicare-Covered Lung Diagnostic Tests Lung Diagnostics Test Portfolio Lung Cancer Risk Assessment Lung Cancer Diagnosis Nodule Risk Assessment Treatment Guidance Testing Identify actionable Identify actionable Identify a patient’s Identify likely Identify likely tumor mutatio

  11. Slide 11: The Challenge in Lung Nodule Management

    Slide 11: The Challenge in Lung Nodule Management

    The Challenge in Lung Nodule Management Balancing CT Surveillance with Intervention The smaller the nodule at Procedures on benign diagnosis, the greater the nodules come at a cost overall 5-year survival3 Surveillance Intervention Majority of lung Diagnosing cancer earlier nodules are benign leads

  12. Slide 12: Standard Lung Cancer Risk Assessment Has Led to Over- and Under-Treatment

    Slide 12: Standard Lung Cancer Risk Assessment Has Led to Over- and Under-Treatment

    Standard Lung Cancer Risk Assessment Has Led to Over- and Under-Treatment of Patients 62% 35% 17% of patients receiving of patients who of patients sent to CT biopsy as the sole underwent surgery had surveillance have diagnostic procedure benign nodules1 malignant nodules2 were benign1 1Silvestri GA

  13. Slide 13: One Blood Draw, Two Tests that Reclassify Risk

    Slide 13: One Blood Draw, Two Tests that Reclassify Risk

    One Blood Draw, Two Tests that Reclassify Risk to Help Reduce Uncertainty in Lung Nodule Management Assessed Risk of Lung Cancer High Risk or (>65%) Patient Chart ~10% of patients identifies likely Biopsy Surgery Clinical Profile malignant nodules with test results in one day • Age (≥40) • Any Smoki

  14. Slide 14: Blood-Based Nodule Risk Assessment

    Slide 14: Blood-Based Nodule Risk Assessment

    Blood-Based Nodule Risk Assessment Ordered together - Run in sequence Rule-Out Test: Identifies patients with lung nodules that Rule-In Test: Identifies patients with lung nodules that are are likely benign likely malignant Proteins on an LC-MS platform from blood Autoantibody detection on an ELISA

  15. Slide 15: Nodify Lung Test: Published Data Package

    Slide 15: Nodify Lung Test: Published Data Package

    Nodify Lung® Test: Published Data Package 1 2 3 4 5 DISCOVERY ANALYTICAL VALIDATION CLINICAL VALIDATION CLINICAL UTILITY HEALTH ECONOMICS & OUTCOMES 2012 2010 2017 2023 2023 Chapman et al, Tumor Murray et al, Annals of Massion et al, Thoracic Oncology Pritchett et al, “ORACLE” Smith et al, ISPOR Bio

  16. Slide 16: Lung Cancer Risk Assessment Before and After Use of Nodify Lung Testing

    Slide 16: Lung Cancer Risk Assessment Before and After Use of Nodify Lung Testing

    Lung Cancer Risk Assessment Before and After Use of Nodify Lung® Testing Biodesix Clinical Utility Review Tool – available for use in clinical consultation with physicians Pre- and Post-test risk of lung cancer for first 110,000 commercial Nodify CDT and Nodify XL2 tests. Same data displayed in scat

  17. Slide 17: Building the Market: Increasing Patient Access in Pulmonology and Primary Care

    Slide 17: Building the Market: Increasing Patient Access in Pulmonology and Primary Care

    Building the Market: Increasing Patient Access in Pulmonology and Primary Care 2024 Breadth of Call Points in US: • ~14,000 pulmonologists • ~15,000 of the ~250K PCPs are active in lung health programs ~50% Managed by Primary Care ~50% Managed by Pulmonology tend to CT surveillance tend to intervene

  18. Slide 18: Therapeutic Guidance Testing Helps Identify the Right Treatment

    Slide 18: Therapeutic Guidance Testing Helps Identify the Right Treatment

    Following Diagnosis, Therapeutic Guidance Testing Helps Identify the Right Treatment for the Right Patient as Quickly as Possible >60 treatments and combinations recommended by NCCN for patients with lung cancer4 ~ 225k 10.5 months 26 days patients diagnosed annually median overall survival of patie

  19. Slide 19: Treatment Guidance Tests for All Stages of Lung Cancer

    Slide 19: Treatment Guidance Tests for All Stages of Lung Cancer

    Treatment Guidance Tests for All Stages of Lung Cancer Early stage Advanced, metastatic, or Lung Cancer recurrent Lung Cancer Immune profiling test Immune profiling test 52-gene test Average turnaround time of 2-3 business days ©2026 Biodesix, Inc. All rights reserved. 27

  20. Slide 20: Rapid Turnaround Blood-Based Tumor & Immune Profiling

    Slide 20: Rapid Turnaround Blood-Based Tumor & Immune Profiling

    Rapid Turnaround Blood-Based Tumor & Immune Profiling 5000 patients enrolled in INSIGHT1 prospective clinical utility study GeneStrat® ddPCR Test GeneStrat NGS® Test VeriStrat® Test Identifies blood-based, guideline Identifies blood-based, guideline Blood-based test identifies a chronic recommended

  21. Slide 21: Product pipeline

    Slide 21: Product pipeline

    Product pipeline For tests outside of lung commercial focus, plan to partner for commercial distribution Test Type Indication Utility Recent Presentations Molecular Residual Genomic Lung and other solid tumor types Recurrence monitoring Memorial Sloan Kettering Disease(MRD) Cancer Center and Bio- Tu

  22. Slide 22: Development Services

    Slide 22: Development Services

    Development Services Biopharmaceutical companies, life sciences tools and diagnostics companies, & academic research institutions

  23. Slide 23: Biodesix Development Services: discovery, test development, and clinical study testing

    Slide 23: Biodesix Development Services: discovery, test development, and clinical study testing

    Biodesix Development Services: strategic and customized discovery, test development, and clinical study testing $8.7M in Development Services under contract Life Sciences Tools Companies & Select Highlights Biopharma Partnerships Academic Research Partners Top Proteomics Company1 Life Sciences Revie

  24. Slide 24: Thank you

    Slide 24: Thank you

    W biodesix: Thank you 33

  25. Slide 25: Appendix

    Slide 25: Appendix

    Appendix W biodesix:

  26. Slide 26: Leadership Team

    Slide 26: Leadership Team

    Leadership Team: Extensive Experience in Diagnostics, Pharma, MedTech, Radiomics, & Healthcare Economics Scott Hutton Robin Harper Cowie Gary Pestano Gary Pestano Jessica Olbricht Brianna Phillips CEO CFO CSO (PhD) CSO (PhD) VP HR VP RA | QA Michael Kammer James Jett Steve Springmeyer Niki Givens He

  27. Slide 27: Board of Directors

    Slide 27: Board of Directors

    Board of Directors: extensive MedTech, Pharma, and Diagnostics industry expertise John Patience Chairman Crabtree Partners LLC Scott Hutton President & CEO Hany Massarany Chair – Compensation Committee Jean Franchi Chair – Audit Committee Matt Strobeck, Ph.D. Chair – Nominations & Governance Committ

  28. Slide 28: Intellectual Property Portfolio

    Slide 28: Intellectual Property Portfolio

    Intellectual Property Portfolio >100 Issued Patents 13 Unique Registered and Filed Trademarks US and International Across 13 Countries Patent Subject Matter: Registered Marks: • VeriStrat® and Nodify® tests and their uses in non-small cell lung • Biodesix • Biodesix Logo and other diseases (e.g., br

  29. Slide 29: In-office blood collection with Tasso+ capillary device

    Slide 29: In-office blood collection with Tasso+ capillary device

    In-office blood collection with Tasso+ capillary device Single-use blood lancing device intended for obtaining capillary whole blood Impact to Lung samples from a patient’s upper arm Nodule Patient Care FDA Class II Lancet 510(k) cleared Improves patient access to Nodify Lung® testing in practices w

Source: company website

More decks from Biodesix, Inc.

All 6 Biodesix decks